Immune response with sipuleucel-T in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Phase II ProACT study

被引：0
|
作者：
Gardner, Thomas A.
Petrylak, Daniel Peter
Corman, John M.
Hall, Simon
Weinstein, Ralph
Keyser, Robert
Sims, Robert Brownell
Sanders, Amanda
Sheikh, Nadeem A.
Higano, Celestia S.
机构：
[1] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA
[2] Columbia Univ, Med Ctr, New York, NY USA
[3] Virginia Mason Med Ctr, Seattle, WA 98101 USA
[4] Mt Sinai Sch Med, New York, NY USA
[5] US Oncol, Portland, OR USA
[6] Dendreon Corp, Seattle, WA USA
[7] Univ Washington, Sch Med, Seattle, WA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 06期
关键词：
D O I：
10.1200/jco.2013.31.6_suppl.148
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
148
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Sipuleucel-T In Metastatic Castration-Resistant Prostate Cancer
    Plosker, Greg L.
    DRUGS, 2011, 71 (01) : 101 - 108
  • [2] SAFETY AND CHANGES IN LABORATORY PARAMETERS ASSOCIATED WITH SIPULEUCEL-T IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: PHASE 2 PROACT STUDY
    Gardner, Thomas
    Petrylak, Daniel
    Corman, John
    Hall, Simon
    Weinstein, Ralph
    Sims, Robert
    DeVries, Todd
    Higano, Celestia
    JOURNAL OF UROLOGY, 2013, 189 (04): : E399 - E399
  • [3] Boosting long-term immune responses to sipuleucel-T (sip-T) by retreatment of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Beer, Tomasz M.
    Corman, John
    Lance, Raymond S.
    Campogan, Dwayne
    Vu, Tuyen
    Haynes, Heather
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [4] Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
    Cal, Cag
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2010, 9 (02): : 76 - 79
  • [5] Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
    Nabhan, Chadi
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (20): : 1966 - 1967
  • [6] Sipuleucel-T (Provenge®) for castration-resistant prostate cancer
    Di Lorenzo, Giuseppe
    Ferro, Matteo
    Buonerba, Carlo
    BJU INTERNATIONAL, 2012, 110 (2B) : E99 - E104
  • [7] Phase II Study with metastatic castration-resistant Prostate Cancer (mCRPC) Patients
    Rexer, H.
    Graefen, M.
    UROLOGE, 2017, 56 (11): : 1468 - 1470
  • [8] Sipuleucel-T in Metastatic Castration-Resistant Prostate CancerProfile Report
    Greg L. Plosker
    BioDrugs, 2011, 25 : 255 - 256
  • [9] Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy
    Peter F. Mulders
    Maria De Santis
    Thomas Powles
    Karim Fizazi
    Cancer Immunology, Immunotherapy, 2015, 64 : 655 - 663
  • [10] IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Pachynski, Russell K.
    Morishima, Chihiro
    Szmulewitz, Russell
    Harshman, Lauren
    Appleman, Leonard
    Monk, Paul
    Bitting, Rhonda L.
    Kucuk, Omer
    Millard, Frederick
    Seigne, John D.
    Fling, Steven P.
    Maecker, Holden T.
    Duault, Caroline
    Ramchurren, Nirasha
    Hess, Bruce
    D'Amico, Leonard
    Lacroix, Andreanne
    Kaiser, Judith C.
    Morre, Michel
    Gregoire, Anne
    Cheever, Martin
    Yu, Evan Y.
    Fong, Lawrence
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (08)
12345